Klotho Neurosciences, Inc.
KLTOW
NASDAQ Global Market0.09
USD
-0.01
- -
CIK
0001907223
ISIN
US49876K1117
CUSIP
49876K111
Return %
Stock
S&P500
1Y
336.55
26.57
3Y
53.57
76.60
5Y
53.57
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph A. Sinkule
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 13576 Walnut Street Omaha NE United States of America 68144
- IPO Date
- Apr 29, 2022
- CIK
- 0001907223
- Website
- klothoneuro.com
- Similar Companies
- Business
- Klotho Neurosciences, Inc. develops innovative cell and gene therapies primarily targeting neurodegenerative and age-related disorders. Its core products include proprietary gene therapy candidates KLTO-101 for Alzheimer's disease and KLTO-202 for amyotrophic lateral sclerosis (ALS), alongside a patented secreted form of the human Klotho protein (s-KL) used to develop transformative protein, cell, and gene treatments. The company’s technology platform, in-licensed exclusively from the Autonomous University of Barcelona, leverages the α-Klotho gene to address diseases such as ALS, Alzheimer's, Parkinson’s, and other age-associated conditions with a focus on extending healthy longevity. Klotho Neurosciences also offers genomics-based diagnostic assays and collaborates on biologic therapies for cancer and cardiovascular diseases. Founded in 2016 and headquartered in Omaha, Nebraska, Klotho has expanded its therapeutic reach with a recently signed Letter of Intent to acquire select assets from Turn Biotechnologies, including Turn’s Epigenetic Reprogramming of Age (ERA) platform and RNA delivery system (eTurna), which enhance regenerative therapy capabilities across dermatology, ophthalmology, immunology, osteoarthritis, and muscle health. This acquisition is anchored by a $300 million out-licensing and co-development partnership with a major South Korean pharmaceutical company, marking a strategic expansion beyond neurodegenerative diseases into broader regenerative medicine applications. Additionally, Klotho terminated a prior share exchange agreement with SkyBell Technologies to focus on its core therapeutics and longevity programs. The company has also initiated manufacturing for its lead gene therapy KLTO-202 and partnered with AAVnerGene Inc. for advanced vector development to improve safety profiles of their gene therapies. Klotho Neurosciences operates within the biotechnology and biopharmaceutical industries, targeting patient populations with neurodegenerative diseases, age-related conditions, and chronic illnesses globally. The company’s pipeline emphasizes life-extending therapies using gene and cell therapy modalities combined with diagnostic tools, aiming to transform outcomes in fields with high unmet medical needs. Recent strategy notably includes broadening its technology portfolio through acquisitions and collaborations to support a wider range of regenerative and therapeutic applications. This comprehensive approach is underpinned by a management team with extensive experience in biopharmaceutical development and commercialization, positioning Klotho Neurosciences as a pioneering entity in the convergence of gene therapy, longevity science, and regenerative medicine. Its ongoing focus on innovation and strategic partnerships manifests in its latest product development and business growth initiatives.
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation